Table 3. CAD (table summarises published studies on CAD in screening, including study design, quality features, and results).
| Reference | Objectivea; comparator | Population (mean age in years) | Test evaluated 1 – In consecutive screenees 2 – Independent of comparator | No. of breast cancers (total sample size) | TPR or Sensitivity | FPR (based on recall rate) |
|---|---|---|---|---|---|---|
| Birdwell et al (2001) Burhenne et al (2000) | I only; M Views: 2 Reader: 1 | Average-risk. CAD assessed on prior M in women later found to have breast cancer | 1–No 2–No (yes for non-cancers) | 542 (14 500) | M: 79% Incremental TPR of CAD=16% | FPR from before after study M: 8.3% CAD: 7.6% |
| Freer and Ulissey (2001) | I only; M Views: 2 Reader: 1 | Average risk | 1–Yes 2–No | 49 (12 860) | M: 83.7% Incremental TPR of CAD=16.3% | M: 6.5% CAD: 7.7% Incremental FPR of CAD=1.2% |
| te Brake et al (1998) | I only; M Views: 1 Reader: 2 | Women subsequently shown to have breast cancer | 1–No 2–No | 65 (207) | Incremental true positives reported (difficult to quantify) | Incremental false positives reported (difficult to quantify) |
CAD=computer-aided diagnosis; M=mammography; ND=not described or unclear from paper; TPR=true-positive rate; FPR=false-positive rate.
a
Objective attainable in using the test: R=replacement for comparator, I=incremental to comparator; Views=number of mammography views per breast, Reader=number of mammography readers.